Literature DB >> 29371290

Protein Tyrosine Phosphatase Receptor Type G (PTPRG) Controls Fibroblast Growth Factor Receptor (FGFR) 1 Activity and Influences Sensitivity to FGFR Kinase Inhibitors.

Michal Kostas1,2, Ellen Margrethe Haugsten2,3, Yan Zhen1,2, Vigdis Sørensen1,2,4, Patrycja Szybowska1,2, Elisa Fiorito2,3, Susanne Lorenz2,3,4, Nina Jones5, Gustavo Antonio de Souza6,7, Antoni Wiedlocha1,2, Jørgen Wesche8,3.   

Abstract

Recently, FGFR1 was found to be overexpressed in osteosarcoma and represents an important target for precision medicine. However, because targeted cancer therapy based on FGFR inhibitors has so far been less efficient than expected, a detailed understanding of the target is important. We have here applied proximity-dependent biotin labeling combined with label-free quantitative mass spectrometry to identify determinants of FGFR1 activity in an osteosarcoma cell line. Many known FGFR interactors were identified (e.g. FRS2, PLCG1, RSK2, SRC), but the data also suggested novel determinants. A strong hit in our screen was the tyrosine phosphatase PTPRG. We show that PTPRG and FGFR1 interact and colocalize at the plasma membrane where PTPRG directly dephosphorylates activated FGFR1. We further show that osteosarcoma cell lines depleted for PTPRG display increased FGFR activity and are hypersensitive to stimulation by FGF1. In addition, PTPRG depletion elevated cell growth and negatively affected the efficacy of FGFR kinase inhibitors. Thus, PTPRG may have future clinical relevance by being a predictor of outcome after FGFR inhibitor treatment.
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29371290      PMCID: PMC5930401          DOI: 10.1074/mcp.RA117.000538

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  54 in total

1.  Two nuclear localization signals required for transport from the cytosol to the nucleus of externally added FGF-1 translocated into cells.

Authors:  Jørgen Wesche; Jedrzej Małecki; Antoni Wiedłocha; Maryam Ehsani; Ewa Marcinkowska; Trine Nilsen; Sjur Olsnes
Journal:  Biochemistry       Date:  2005-04-26       Impact factor: 3.162

Review 2.  Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.

Authors:  Maria Vittoria Dieci; Monica Arnedos; Fabrice Andre; Jean Charles Soria
Journal:  Cancer Discov       Date:  2013-02-15       Impact factor: 39.397

3.  Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase.

Authors:  Tingting Sun; Nicola Aceto; Kristen L Meerbrey; Jessica D Kessler; Chunshui Zhou; Ilenia Migliaccio; Don X Nguyen; Natalya N Pavlova; Maria Botero; Jian Huang; Ronald J Bernardi; Earlene Schmitt; Guang Hu; Mamie Z Li; Noah Dephoure; Steven P Gygi; Mitchell Rao; Chad J Creighton; Susan G Hilsenbeck; Chad A Shaw; Donna Muzny; Richard A Gibbs; David A Wheeler; C Kent Osborne; Rachel Schiff; Mohamed Bentires-Alj; Stephen J Elledge; Thomas F Westbrook
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

4.  A tyrosine-phosphorylated carboxy-terminal peptide of the fibroblast growth factor receptor (Flg) is a binding site for the SH2 domain of phospholipase C-gamma 1.

Authors:  M Mohammadi; A M Honegger; D Rotin; R Fischer; F Bellot; W Li; C A Dionne; M Jaye; M Rubinstein; J Schlessinger
Journal:  Mol Cell Biol       Date:  1991-10       Impact factor: 4.272

5.  Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models.

Authors:  James G Taylor; Adam T Cheuk; Patricia S Tsang; Joon-Yong Chung; Young K Song; Krupa Desai; Yanlin Yu; Qing-Rong Chen; Kushal Shah; Victoria Youngblood; Jun Fang; Su Young Kim; Choh Yeung; Lee J Helman; Arnulfo Mendoza; Vu Ngo; Louis M Staudt; Jun S Wei; Chand Khanna; Daniel Catchpoole; Stephen J Qualman; Stephen M Hewitt; Glenn Merlino; Stephen J Chanock; Javed Khan
Journal:  J Clin Invest       Date:  2009-10-05       Impact factor: 14.808

6.  Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy.

Authors:  M Fernanda Amary; Hongtao Ye; Fitim Berisha; Bhavisha Khatri; Georgina Forbes; Katie Lehovsky; Anna M Frezza; Sam Behjati; Patrick Tarpey; Nischalan Pillay; Peter J Campbell; Roberto Tirabosco; Nadège Presneau; Sandra J Strauss; Adrienne M Flanagan
Journal:  Cancer Med       Date:  2014-05-27       Impact factor: 4.452

7.  Proximity biotinylation and affinity purification are complementary approaches for the interactome mapping of chromatin-associated protein complexes.

Authors:  Jean-Philippe Lambert; Monika Tucholska; Christopher Go; James D R Knight; Anne-Claude Gingras
Journal:  J Proteomics       Date:  2014-10-02       Impact factor: 4.044

8.  2016 update of the PRIDE database and its related tools.

Authors:  Juan Antonio Vizcaíno; Attila Csordas; Noemi del-Toro; José A Dianes; Johannes Griss; Ilias Lavidas; Gerhard Mayer; Yasset Perez-Riverol; Florian Reisinger; Tobias Ternent; Qing-Wei Xu; Rui Wang; Henning Hermjakob
Journal:  Nucleic Acids Res       Date:  2015-11-02       Impact factor: 16.971

9.  Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1.

Authors:  D Weekes; T G Kashima; C Zandueta; N Perurena; D P Thomas; A Sunters; C Vuillier; A Bozec; E El-Emir; I Miletich; A Patiño-Garcia; F Lecanda; A E Grigoriadis
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

10.  Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene.

Authors:  Tale Barøy; Chandra S R Chilamakuri; Susanne Lorenz; Jinchang Sun; Øyvind S Bruland; Ola Myklebost; Leonardo A Meza-Zepeda
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

View more
  15 in total

1.  Exploration of Potential Ewing Sarcoma Drugs from FDA-Approved Pharmaceuticals through Computational Drug Repositioning, Pharmacogenomics, Molecular Docking, and MD Simulation Studies.

Authors:  Mubashir Hassan; Muhammad Yasir; Saba Shahzadi; Andrzej Kloczkowski
Journal:  ACS Omega       Date:  2022-06-01

2.  Proximity-Dependent Biotinylation to Elucidate the Interactome of TNK2 Nonreceptor Tyrosine Kinase.

Authors:  Raiha Tahir; Anil K Madugundu; Savita Udainiya; Jevon A Cutler; Santosh Renuse; Li Wang; Nicole A Pearson; Christopher J Mitchell; Nupam Mahajan; Akhilesh Pandey; Xinyan Wu
Journal:  J Proteome Res       Date:  2021-08-24       Impact factor: 4.466

3.  ROR1 Potentiates FGFR Signaling in Basal-Like Breast Cancer.

Authors:  Gaurav Pandey; Nicholas Borcherding; Ryan Kolb; Paige Kluz; Wei Li; Sonia Sugg; Jun Zhang; Dazhi A Lai; Weizhou Zhang
Journal:  Cancers (Basel)       Date:  2019-05-24       Impact factor: 6.575

Review 4.  Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins.

Authors:  Marta Latko; Aleksandra Czyrek; Natalia Porębska; Marika Kucińska; Jacek Otlewski; Małgorzata Zakrzewska; Łukasz Opaliński
Journal:  Cells       Date:  2019-05-14       Impact factor: 6.600

5.  Differential regulation of fibroblast growth factor receptor 1 trafficking and function by extracellular galectins.

Authors:  Marika Kucińska; Natalia Porębska; Agata Lampart; Marta Latko; Agata Knapik; Małgorzata Zakrzewska; Jacek Otlewski; Łukasz Opaliński
Journal:  Cell Commun Signal       Date:  2019-06-17       Impact factor: 5.712

6.  Cancer Mutations in FGFR2 Prevent a Negative Feedback Loop Mediated by the ERK1/2 Pathway.

Authors:  Patrycja Szybowska; Michal Kostas; Jørgen Wesche; Antoni Wiedlocha; Ellen Margrethe Haugsten
Journal:  Cells       Date:  2019-05-29       Impact factor: 6.600

7.  Development of a Machine Learning-Based Autophagy-Related lncRNA Signature to Improve Prognosis Prediction in Osteosarcoma Patients.

Authors:  Guang-Zhi Zhang; Zuo-Long Wu; Chun-Ying Li; En-Hui Ren; Wen-Hua Yuan; Ya-Jun Deng; Qi-Qi Xie
Journal:  Front Mol Biosci       Date:  2021-05-21

Review 8.  Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling.

Authors:  Harriet R Ferguson; Michael P Smith; Chiara Francavilla
Journal:  Cells       Date:  2021-05-14       Impact factor: 6.600

Review 9.  Negative Regulation of FGFR (Fibroblast Growth Factor Receptor) Signaling.

Authors:  Patrycja Szybowska; Michal Kostas; Jørgen Wesche; Ellen Margrethe Haugsten; Antoni Wiedlocha
Journal:  Cells       Date:  2021-05-28       Impact factor: 6.600

Review 10.  Cell Communications among Microorganisms, Plants, and Animals: Origin, Evolution, and Interplays.

Authors:  Yves Combarnous; Thi Mong Diep Nguyen
Journal:  Int J Mol Sci       Date:  2020-10-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.